Every lot published · search any lot number before you order

Retatrutide TRIUMPH-3 and Established Cardiovascular Disease

TRIUMPH-3 is a phase 3 retatrutide trial in adults with severe obesity and established cardiovascular disease. Its study population makes it different from the broader obesity program. Lilly released topline results in July 2026. The figures below come from that sponsor announcement.

The TRIUMPH-3 question. Established heart disease. Weight at week 80. Sponsor-reported data.GLP LIFE SCIENCES · RESEARCH NOTESThe TRIUMPH-3 questionEstablished heart diseaseWeight at week 80Sponsor-reported data

What was the main outcome?

The sponsor reported percentage change in body weight at 80 weeks. In the efficacy-estimand analysis, mean reductions were 21.6% and 22.6% in the two assigned retatrutide groups, compared with 3.2% in the placebo group. That analysis reflects the sponsor’s stated assumptions about events such as stopping study treatment. A treatment-regimen estimate answers a different question.

What did the trial report about cardiovascular risk factors?

The release described changes in measures such as blood pressure, triglycerides and waist circumference. These measurements can help explain how the groups differed during follow-up. A change in a risk factor cannot establish a reduction in heart attacks or strokes. TRIUMPH-Outcomes is a separate study designed to evaluate serious cardiovascular and kidney outcomes.

What safety context is available?

The sponsor reported adverse events including diarrhea, nausea and constipation. Check how often events occurred in placebo and both assigned treatment groups. Treatment discontinuation and events that occur infrequently may require more detail than a topline release provides.

What can a reader verify today?

Use the registry to confirm the population, the outcomes and the planned duration. Use the sponsor release to trace each numerical result to its analysis label. When detailed results are available, compare them with the topline figures and note any differences in the analysis used. The study concerns investigational retatrutide.

Sources and further reading

TRIUMPH-3 trial registration · Lilly’s July 2026 topline release · Lilly’s TRIUMPH-3 study summary · FDA’s information on unapproved GLP-1 drugs

GLP Life Sciences research library · Existing TRIUMPH-1 research summary